Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Retained Earnings (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Retained Earnings for 12 consecutive years, with -$682.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings fell 1706192.5% year-over-year to -$682.4 million, compared with a TTM value of -$682.4 million through Sep 2025, down 1706192.5%, and an annual FY2024 reading of $27000.0, up 100.0% over the prior year.
  • Retained Earnings was -$682.4 million for Q3 2025 at CytomX Therapeutics, down from $33000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $40000.0 in Q3 2024 and bottomed at -$727.3 million in Q2 2023.
  • Average Retained Earnings over 5 years is -$423.1 million, with a median of -$588.7 million recorded in 2021.
  • The sharpest move saw Retained Earnings plummeted 3486075.0% in 2021, then skyrocketed 925.0% in 2025.
  • Year by year, Retained Earnings stood at -$242000.0 in 2021, then tumbled by 298610.33% to -$722.9 million in 2022, then dropped by 0.08% to -$723.4 million in 2023, then skyrocketed by 100.0% to $27000.0 in 2024, then plummeted by 2527644.44% to -$682.4 million in 2025.
  • Business Quant data shows Retained Earnings for CTMX at -$682.4 million in Q3 2025, $33000.0 in Q2 2025, and -$1000.0 in Q1 2025.